Long-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus-Related Cirrhosis

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 1, 2013, Pages 88-94

  Köklü, Seyfettin ^a   Tuna, Yaşar ^b   Gülşen, Murat Taner ^c   Demir, Mehmet ^d   Köksal, Aydin şeref ^e   Koçkar, Muhammet Cem ^f   Aygün, Cem ^g   Çoban, şahin ^h   Özdil, Kamil ^h   Ataseven, Hüseyin ⁱ   Akin, Ebru ^j   Pürnak, Tuǧrul ^k   Yüksel, ilhami ^h   Ataseven, Hilmi ^l   ibiş, Mehmet ^m   Yildirim, Beytullah ⁿ   Nadir, Işilay ^o   Küçükazman, Metin ^h   Akbal, Erdem ^k   Yüksel, Osman ^h   Başar, Ömer ^b   Alkan, Erhan ^b   Baykal, Özlem ^f   more..

^a HACETTEPE UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

^c GAZIANTEP UNIVERSITY   (Turkey)

^d MUSTAFA KEMAL UNIVERSITY   (Turkey)

^e TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^f SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g FIRAT UNIVERSITY   (Turkey)

^h Dişkapi Education and Research Hospital ^*  (Turkey)

ⁱ SELCUK UNIVERSITY   (Turkey)

^j ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^k ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^l CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^m GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

ⁿ ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^o FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; INTERFERON; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CHILD TURCOTTE PUGH SCORE; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPOPHOSPHATEMIA; KIDNEY DYSFUNCTION; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RATING SCALE; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH VARICES BLEEDING; TREATMENT OUTCOME; TURKEY (REPUBLIC); VIRUS LOAD; VIRUS STRAIN;

ADENINE; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BLOOD CHEMICAL ANALYSIS; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TURKEY;

EID: 84870925895     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.10.003     Document Type: Article

References (26)

1. Guan R., Lui H.F. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol 2011, 2011:918017.
2. de Jongh F.E., Janssen H.L., de Man R.A., et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103:1630-1635.
3. Massoumi H., Martin P., Tan H.H. Management of chronic hepatitis B. Eur J Gastroenterol Hepatol 2011, 23:642-650.
4. Yao F.Y., Bass N.M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000, 33:301-307.
5. Fontana R.J., Hann H.W., Perrillo R.P., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002, 123:719-727.
6. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
7. Schiff E.R., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003, 38:1419-1427.
8. Schiff E., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13:349-360.
9. Gane E.C., Chan H.L., Choudhuri G., et al. Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine. J Hepatol 2010, 52:S1-S21.
10. Shim J.H., Lee H.C., Kim K.M., et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010, 52:176-182.
11. Liaw Y.S., Sheen I.S., Lee C.M., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53:62-72.
12. Buti M., Hadziyannis S., Mathurin P., et al. Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis. J Hepatol 2009, 50:S10-S11.
13. Tan H.H., Martin P. Management of end-stage liver disease in chronic hepatitis B. Clin Liver Dis 2010, 14:477-493.
14. Shamliyan T.A., MacDonald R., Shaukat A., et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009, 150:111-124.
15. Lim S.G., Aung M.O., Mak B., et al. Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. J Clin Gastroenterol 2011, 45:818-823.
16. Fontana R.J. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol 2010, 52:147-149.
17. Kao J.T.P.C., Lai H.C., Chuang P.H., et al. Efficacy of entecavir in naive patients with chronic hepatitis B and decompensated liver cirrhosis. J Gastrotroenterol Hepatol 2009, 24:A202.
18. Liaw Y.S., Raptopoulou-Gigi M., Cheinquer H., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: randomized, open label study. Hepatology 2011, 54:91-100.
19. Pellicelli A.M., Barbarini G., Romano M., et al. Entecavir therapy for lamivudine resistant HBV cirrhotic patients waiting for OLT: viral and biochemical outcomes at one year. Hepatology 2009, 50:514A.
20. Singal A.K., Fontana R.J. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012, 35:674-689.
21. Zoulim F., Radenne S., Ducerf C. Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis. Liver Transplant 2008, 14(Suppl 2):S1-S7.
22. Yao F.Y., Terrault N.A., Freise C., et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001, 34:411-416.
23. Kapoor D., Guptan R.C., Wakil S.M., et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000, 33:308-312.
24. Manolakopoulos S., Karatapanis S., Elefsiniotis J., et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to hepatitis B e Ag negative chronic HBV infection. Am J Gastroenterol 2003, 99:57-63.
25. Fontana R.J., Keeffe E.B., Carey W., et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002, 8:433-439.
26. Seo Y.S., Jung F.S., Kim J.H., et al. Lamivudine versus entecavir in patients with hepatitis B virus related decompensated liver cirrhosis. J Hepatol 2010, 50:550A.